PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer - Schwartzberg, L S; Rivera, F; Karthaus, M (Journal of clinical oncology official journal of the American Society of Clinical Oncology, 2014)
et al.